Lilly To Focus Mainly On Pipeline Development As It Faces Steep Patent Cliff
This article was originally published in The Pink Sheet Daily
With generic competition around the corner for blockbusters like Zyprexa, Lilly can't count on many more quarters like the past one's 16 percent net income growth.
You may also be interested in...
Alnara hopes to leverage Lilly's prior success with recombinant insulin products.
Already a leader in emergency kits, Lilly will support trials on a simpler device that doesn't require complex preparation.
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.